Diindolylmethane in Treating Patients With Stage I or Stage II Prostate Cancer Undergoing Radical Prostatectomy

OBJECTIVES:

Primary

- To measure the level of diindolylmethane in prostate tissue after treatment with oral
microencapsulated diindolylmethane (B-DIM) in patients with stage I or II adenocarcinoma
of the prostate undergoing radical prostatectomy.

Secondary

- To measure serum biomarkers (e.g., total PSA, serum testosterone, and diindolylmethane
levels) pre- and post-treatment with B-DIM.

- To measure tissue biomarkers (e.g., androgen receptor, NF-κB, and PSA) pre- and
post-treatment with B-DIM.

OUTLINE: This is a multicenter study.

Patients receive oral microencapsulated diindolylmethane (B-DIM) twice daily for 14-72 days
in the absence of disease progression or unacceptable toxicity. Patients then undergo radical
prostatectomy 1 day after the last dose of B-DIM.

Patients undergo blood and tissue sample collection for correlative laboratory studies. Blood
samples are analyzed for serum PSA, testosterone, and diindolylmethane levels by high
performance liquid chromatography and tandem mass spectrometry (LC-MS/MS). Tissue samples are
analyzed for diindolylmethane concentration by LC-MS/MS and for androgen receptor, activated
NF-κB (p65 antibody), and PSA expression by IHC.

DISEASE CHARACTERISTICS:

- Histologically or cytologically confirmed adenocarcinoma of the prostate

- Stage I or II (T1-T2 a, b, or c) disease

- Disease confined to the prostate by clinical judgment of the surgeon

- Deemed an appropriate candidate for surgery by clinical judgment of the surgeon

PATIENT CHARACTERISTICS:

- ECOG performance status 0-2

- ANC ≥ 1,500/mm³

- Platelet count ≥ 100,000/mm³

- Hemoglobin ≥ 8.0 g/dL

- Total bilirubin ≤ 1.5 times upper limit of normal (ULN)

- AST and/or ALT ≤ 2.5 times ULN if alkaline phosphatase normal OR alkaline phosphatase
≤ 4 times ULN if AST and/or ALT normal

- Serum creatinine ≤ 2.0 mg/dL

- No history of allergic reactions attributed to compounds of similar chemical or
biological composition to oral microencapsulated diindolylmethane

- No concurrent uncontrolled illness including, but not limited to, any of the
following:

- Ongoing or active infection

- Symptomatic congestive hart failure

- Unstable angina pectoris

- Cardiac arrhythmia

- Psychiatric illness or social situation that would limit compliance with study
requirements

PRIOR CONCURRENT THERAPY:

- No prior chemotherapy, hormonal therapy, brachytherapy, cryotherapy, external beam
radiotherapy, or other therapy for prostate cancer

- No concurrent micronutrient supplements or dietary soy products

- No concurrent systemic therapy for any other cancer

- No concurrent p450 inducers or inhibitors (e.g., carbamazepine, clarithromycin,
fluconazole, fosphenytoin, itraconazole, ketoconazole, phenobarbital, phenytoin,
rifabutin, or rifampin)

- No concurrent finasteride or dutasteride

- No other concurrent investigational or commercial agents or therapies for the
malignancy